We offer several clinical trials for multiple types of cancer and participate in as many as 50 to 100 clinical trials with partnering cancer centers. These clinical trials give our patients access to emerging treatment options right here in Spokane, eliminating the need to travel outside of the Inland Northwest for the latest in cancer treatment. The clinical trials also provide important information to help conquer cancer.
Before beginning treatment, you may want to consider participating in a clinical trial. Talk with your medical oncologist, surgical oncologist or radiation oncologist to determine if this is a good option for you.
What is a clinical trial?
Clinical trials are research studies that help determine the effectiveness of a new drug or treatment. Each clinical trial is designed to answer specific scientific questions and to help find potentially better ways to prevent, diagnose or treat cancer.
Why are clinical trials important?
Clinical trials are a vital part of the process in finding new cancer treatments and ultimately a cure for cancer. Without these research studies, many of the advances we see today in cancer detection, treatment and prevention would never have happened.
For More Information
If you are interested in a clinical trial and would like more information to discuss with our Cancer Care Northwest physician, please email the Cancer Care Northwest Research Department at email@example.com for more information. Be sure to include:
Using the dropdown menu below, you can search and request more information for open trials.
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).View Details
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC).View Details
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer.View Details
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011).View Details
Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)View Details